1
|
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol 2022; 23:93-104. [PMID: 34674160 PMCID: PMC8776677 DOI: 10.1007/s40257-021-00650-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/12/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND A three-pronged approach to acne treatment-combining an antibiotic, antibacterial, and retinoid-could provide greater efficacy and tolerability than single or dyad treatments, while potentially improving patient compliance and reducing antibiotic resistance. OBJECTIVES We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS In a phase II, double-blind, multicenter, randomized, 12-week study, eligible participants aged ≥ 9 years with moderate-to-severe acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels: BPO/adapalene; clindamycin phosphate/BPO; or clindamycin phosphate/adapalene. Coprimary endpoints were treatment success at week 12 (participants achieving a ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin) and least-squares mean absolute changes from baseline in inflammatory and noninflammatory lesion counts to week 12. Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed. RESULTS A total of 741 participants were enrolled. At week 12, 52.5% of participants achieved treatment success with IDP-126 vs vehicle (8.1%) and dyads (range 27.8-30.5%; P ≤ 0.001, all). IDP-126 also provided significantly greater absolute reductions in inflammatory (29.9) and noninflammatory (35.5) lesions compared with vehicle or dyads (range inflammatory, 19.6-26.8; noninflammatory, 21.8-30.0; P < 0.05, all), corresponding to > 70% reductions with IDP-126. IDP-126 was well tolerated, with most treatment-emergent adverse events of mild-to-moderate severity. CONCLUSIONS Once-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel demonstrated superior efficacy to vehicle and all three dyad component gels, and was well tolerated over 12 weeks in pediatric, adolescent, and adult participants with moderate-to-severe acne. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier NCT03170388 (registered 31 May, 2017).
Collapse
Affiliation(s)
- Linda Stein Gold
- Henry Ford Hospital, 6530 Farmington Rd, Ste 101, West Bloomfield, Detroit, MI, 48322, USA.
| | - Hilary Baldwin
- The Acne Treatment and Research Center, Brooklyn, NY, USA
- Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
| | - Leon H Kircik
- Indiana University School of Medicine, Indianapolis, IN, USA
- Physicians Skin Care, PLLC, Louisville, KY, USA
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jonathan S Weiss
- Georgia Dermatology Partners, Snellville, GA, USA
- Gwinnett Clinical Research Center, Inc., Snellville, GA, USA
| | - David M Pariser
- Eastern Virginia Medical School, Norfolk, VA, USA
- Virginia Clinical Research, Inc., Norfolk, VA, USA
| | - Valerie Callender
- Callender Dermatology and Cosmetic Center, Glenn Dale, MD, USA
- Howard University College of Medicine, Washington, DC, USA
| | - Edward Lain
- Austin Institute for Clinical Research, Austin, TX, USA
| | - Michael Gold
- Tennessee Clinical Research Center, Nashville, TN, USA
| | - Kenneth Beer
- University of Miami Miller School of Medicine, Miami, FL, USA
| | - Zoe Draelos
- Dermatology Consulting Services, PLLC, High Point, NC, USA
| | - Neil Sadick
- Weill Cornell Medical College, New York, NY, USA
- Sadick Dermatology, New York, NY, USA
| | | | | | | |
Collapse
|
2
|
Kaminska EC. Treatment of acne and acne-related scarring with fixed combination clindamycin phosphate and benzoyl peroxide gel (1.2%/3.75%) and tretinoin gel microsphere 0.06% in an Asian American transgender female. SAGE Open Med Case Rep 2021; 8:2050313X20984038. [PMID: 33447388 PMCID: PMC7780311 DOI: 10.1177/2050313x20984038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Accepted: 12/07/2020] [Indexed: 11/25/2022] Open
Abstract
Acne vulgaris is one of the most common skin diseases in the United States and can affect any gender or ethnic group. Post-inflammatory hyperpigmentation (PIH) and scarring from acne can have a negative psychosocial impact on patients. Skin of color patients are particularly prone to PIH, as the dark marks left from acne may take several months to resolve, far after the acne has cleared. Here, we report a case of moderate acne with associated scarring in a transgender, Asian American female who was successfully treated with fixed combination topical therapy with clindamycin phosphate and benzoyl peroxide gel 1.2%/3.75% and tretinoin gel microsphere 0.06%.
Collapse
|